ArticleBioengineering (Basel, Switzerland)2026
Post-Marketing Safety Profile of Mirikizumab: A Multi-Database Pharmacovigilance Study Using FAERS and JADER with IL-23 Inhibitor Class Comparison.
Jeong-Gyu Choi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.